Does the COVID-19 Vaccine Contain Monkey DNA?

COVID-19 vaccines do not contain monkey DNA. The claim circulates widely online but conflates several unrelated aspects of vaccine science: a short viral DNA sequence called the SV40 promoter-enhancer found in manufacturing plasmids, the use of a chimpanzee-derived adenovirus shell in one vaccine platform, and a genuine historical episode from the 1950s in which a monkey virus contaminated early polio vaccines. None of these amount to monkey DNA being present in any COVID-19 vaccine you could receive, but each thread of the story is worth untangling because the confusion is understandable.

Where the Claim Actually Comes From

Most versions of the “monkey DNA” claim trace back to the discovery that the Pfizer-BioNTech mRNA vaccine’s manufacturing plasmid contains a sequence derived from Simian Virus 40, usually abbreviated SV40. SV40 is a polyomavirus that was originally isolated from rhesus macaque kidney cells in the late 1950s and early 1960s, when those cells were being used to grow poliovirus for vaccines.¹ The name “simian” understandably makes people think of monkey genetic material. But the SV40 sequence used in modern molecular biology is a tiny, well-characterized stretch of viral DNA that functions as a genetic switch. It is not monkey chromosomal DNA, and it was not pulled fresh from a primate. It has been a standard tool in laboratory plasmids for decades.

The confusion is amplified by a separate fact: one of the COVID-19 vaccine platforms, the Oxford-AstraZeneca shot, uses a viral vector derived from a chimpanzee adenovirus. That sounds even more like “monkey material,” and in a narrow technical sense the vector’s backbone does originate from a primate virus. But the vector is so heavily re-engineered that calling it monkey DNA is like calling a modern skyscraper a pile of sand because concrete starts with it.

The SV40 Promoter-Enhancer in mRNA Vaccine Plasmids

To make the mRNA that goes into Pfizer or Moderna shots, manufacturers start with a circular piece of DNA called a plasmid. That plasmid serves as a template: an enzyme reads it and produces the mRNA strand encoding the SARS-CoV-2 spike protein. After transcription, the plasmid is supposed to be broken down and removed. In the Pfizer plasmid, one of the regulatory sequences that helps the plasmid function in bacterial and mammalian cell systems is the SV40 promoter-enhancer-origin of replication region.

This is a short stretch of DNA, not a genome. SV40’s full genome is only about 5,200 base pairs, and the promoter-enhancer fragment used in the plasmid is even smaller. The SV40 enhancer consists of a few functional units that cooperate to boost gene transcription.² Scientists have used this sequence for decades because it is efficient at driving gene expression in laboratory settings. It was not included in the Pfizer plasmid to introduce monkey material into people; it was included because it is a workhorse element in molecular cloning. The Moderna plasmid, for its part, does not contain the SV40 promoter-enhancer sequence at all.

How Much Residual DNA Actually Ends Up in the Vials

The plasmid template is supposed to be degraded and washed away before the final vaccine is bottled, but trace amounts survive the purification process. This is true of essentially all biologics manufacturing, and regulators have long set limits for how much leftover DNA is acceptable. The WHO and FDA recommend that a finished dose contain no more than 10 nanograms of residual DNA, with fragment sizes below 200 base pairs.³

Whether the mRNA vaccines consistently meet those limits has been debated. One Canadian study that tested 32 vials across 16 vaccine lots found total DNA ranging from roughly 370 to 1,550 nanograms per dose in Pfizer products and about 1,130 to 6,280 nanograms per dose in Moderna products when measured by a fluorescence-based method.⁴ Those numbers sound alarming relative to the 10-nanogram guideline. However, the same study found that when specific plasmid DNA targets were measured by a more targeted method, the amounts were far lower: 0.22 to 7.28 nanograms per dose for Pfizer and 0.01 to 0.78 nanograms per dose for Moderna. The discrepancy matters because the fluorescence method picks up all nucleic acids, including the massive amount of mRNA that is supposed to be there, and can overestimate DNA content.

A separate European analysis using four independent measurement approaches found that all 15 tested batches of both Pfizer’s Comirnaty and Moderna’s Spikevax vaccines fell below approved residual DNA limits.⁵ A third study confirmed a DNA-to-RNA mass ratio of about 1:1,000, consistent with approved specifications, and concluded that earlier claims of dramatically higher DNA contamination were artifacts of the measurement technique used, specifically the interference caused by high concentrations of RNA and lipids in the sample.⁶ The disagreement between studies comes down largely to methodology: how you handle the overwhelming amount of mRNA in the sample before you try to count the tiny amount of DNA underneath it.

The SV40 Promoter Fragment as a Specific Concern

Even if total residual DNA levels are low, some researchers have flagged a more targeted worry: the SV40 promoter-enhancer fragment itself. In the Canadian study, the SV40 sequence was detected at 0.25 to 23.72 nanograms per dose in Pfizer vials, with two of six Pfizer lots exceeding the regulatory limit for that specific fragment by about twofold. It was not detected in any Moderna vials.⁴ This is significant not because the fragment is “monkey DNA” but because of what the SV40 enhancer can do in laboratory settings.

Research has shown that the 72-base-pair repeats of the SV40 enhancer can help plasmid DNA get transported into a cell’s nucleus, even in cells that are not actively dividing.⁷ In gene therapy, that is a useful property: you want your therapeutic DNA to reach the nucleus. In a vaccine where residual DNA is an unintended contaminant, the same property is less welcome, because it raises theoretical questions about whether leftover plasmid fragments carrying the SV40 enhancer could find their way into the nuclei of vaccinated cells. The fragments found in vaccine vials were mostly short, with an average length of about 214 base pairs and a maximum of 3,500 base pairs based on sequencing of one vial.⁴ Short DNA fragments are generally considered less likely to integrate into human chromosomes, but the presence of the SV40 enhancer on those fragments is what keeps the discussion alive among scientists who study DNA integration risk.

The interest in measuring residual DNA in biologics has always been partly about theoretical safety concerns, specifically the remote possibility that certain DNA sequences could be infectious or carry cancer-promoting potential, depending on the host cell system used.⁸ These are hypothetical risks that the 10-nanogram limit was designed to guard against. Whether residual SV40 enhancer fragments at the levels found in some Pfizer vials pose any real-world danger remains an open and contested question, but it is a legitimate scientific question about manufacturing quality control, not evidence that monkey genetic material was injected into anyone.

The Chimpanzee Adenovirus in the AstraZeneca Vaccine

A completely different thread of the “monkey DNA” claim involves the Oxford-AstraZeneca vaccine, sold as Vaxzevria, which uses a viral vector called ChAdOx1. This vector is based on a chimpanzee adenovirus known as Y25. The reason scientists chose a chimpanzee virus rather than a human one is practical: most adults have already been exposed to common human adenoviruses and carry antibodies against them. If you build a vaccine on a human adenovirus, many people’s immune systems will attack the vector itself before it delivers its cargo. A chimpanzee adenovirus sidesteps that problem because few humans have pre-existing immunity to it.⁹

The ChAdOx1 vector is not a live chimpanzee virus. Its E1 gene has been deleted to make it unable to replicate, and additional modifications to its E3 and E4 genes allow it to carry the spike protein gene and be grown efficiently in manufacturing cells. What remains is essentially an empty delivery shell with chimpanzee adenoviral structural proteins on the outside and a human-designed gene cassette on the inside. The vector enters your cells, delivers the spike protein instructions, and cannot make copies of itself. The chimpanzee-origin DNA in the vector encodes the structural shell, not any monkey chromosomal material, and the vector DNA does not integrate into human chromosomes as part of normal function.

The Johnson & Johnson vaccine used a different approach: a human adenovirus type 26 (Ad26) vector, manufactured in the PER.C6 cell line, which is a human retinal cell line. The Ad26 vector includes an SV40 polyadenylation sequence, a short signal element that tells the cell where to stop reading the gene, but no SV40 promoter-enhancer.¹⁰ Neither the J&J nor the Moderna vaccine involves primate-derived viral vectors or primate cell lines in their production.

The 1950s Polio Vaccine Episode That Haunts Modern Vaccines

The deepest root of the “monkey DNA in vaccines” fear predates COVID-19 by more than sixty years. In the 1950s and early 1960s, polio vaccines were produced using primary kidney cells harvested directly from rhesus macaques. Those cells turned out to harbor SV40, which was not yet known to science. As a result, millions of doses of polio vaccine were inadvertently contaminated with live SV40 virus.¹ This was a real event and a serious manufacturing failure. When SV40 was discovered and characterized in 1960, vaccine production methods were changed to screen for and eliminate the virus.

Decades of follow-up research have investigated whether people who received SV40-contaminated polio vaccines experienced higher rates of cancer. The overall epidemiological evidence has not established a clear link, though the question generated enormous scientific literature and public anxiety. That historical episode is the emotional foundation for today’s concerns. When people hear “SV40” and “vaccine” in the same sentence, the 1950s contamination is the story their pattern-matching brain reaches for. The crucial difference is that the 1950s problem involved a live, replicating virus that was an unknown contaminant. The SV40 sequences in modern vaccine plasmids are short, non-replicating DNA fragments that were deliberately placed there as a molecular tool and are present only as manufacturing residue.

What the Residual DNA Actually Consists Of

Sequencing studies have characterized the identity of the leftover DNA in mRNA vaccine vials. In the European four-method analysis, bioinformatic assembly of sequencing reads showed that the DNA fragments were overwhelmingly derived from the plasmid template used during manufacturing. In Comirnaty (Pfizer) vaccines, plasmid-derived sequences accounted for about 97% of total reads, and in Spikevax (Moderna) vaccines, about 89%.⁵ In other words, the residual DNA is not some mysterious contaminant from an unknown source. It is leftover pieces of the manufacturing tool, broken into small fragments during the purification process. The remaining reads likely come from bacterial host DNA used to grow the plasmid, which is also standard in biologics and is not primate in origin.

This matters because the fear narrative often implies that some unidentified foreign DNA has been smuggled into the vaccine. The sequencing evidence shows the opposite: the DNA traces are fully accounted for and match exactly what you would expect from the manufacturing process.

Why the Measurement Controversy Persists

If the question sounds settled, you might wonder why researchers keep publishing papers about it. The answer is methodological. Measuring trace DNA in the presence of massive amounts of mRNA and lipid nanoparticle components is technically finicky. The mRNA itself can interfere with fluorescence-based DNA measurements, inflating the apparent DNA count. Different extraction protocols, different quantification methods, and different ways of handling the lipid envelope that wraps the mRNA all influence the result.

One group of researchers found what they described as 534-fold higher amounts of DNA than expected. The subsequent European study demonstrated that those claims were a consequence of failing to account for the interference caused by the extraordinary concentrations of RNA and lipids in the sample.⁶ When properly handled, the DNA-to-RNA ratio came out at about 1:1,000, which is what the manufacturers’ specifications predict. The Canadian study that reported higher total DNA values also noted the discrepancy between its broad fluorometry measurements and its targeted quantitative PCR results, with the PCR results generally falling within or near regulatory limits.⁴

The honest summary is that the field has not fully converged on a single gold-standard method for quantifying residual DNA in lipid nanoparticle-encapsulated mRNA products. This is a new product category, and analytical methods are still catching up. That ambiguity creates space for both genuine scientific debate and for bad-faith actors to cherry-pick the highest numbers from the least appropriate methods.

Adenovirus Vaccines and Host Cell DNA

For the adenovirus-vectored vaccines, a parallel issue exists: residual host cell DNA from the cell lines used to grow the vector. The AstraZeneca vaccine was produced in human embryonic kidney (HEK 293) cells, and the J&J vaccine in PER.C6 cells. Both are human cell lines, not primate cell lines. Manufacturing processes for adenovirus vaccines include purification steps designed to clear host cell proteins and DNA. A recent study on adenovirus purification demonstrated that optimized chromatography processes can reduce host cell DNA to about 44 nanograms per dose while recovering roughly half of the infectious viral particles.¹¹ That level meets clinical requirements, though it is above the 10-nanogram WHO guideline that applies to other biologics. Regulatory agencies evaluate adenoviral vector products under their own frameworks, taking into account the specific risk profile of the vector platform.

For the AstraZeneca vaccine specifically, the host cell DNA that might be present as residue is human DNA from HEK 293 cells, not monkey DNA. The chimpanzee-origin component is the adenoviral vector backbone itself, which is the active ingredient, not a contaminant. Conflating these two things, the intentional vector and the residual host cell material, is another source of confusion in public discussions.

Vero Cells and Other Primate Cell Lines in Broader Vaccine Manufacturing

Some vaccines unrelated to COVID-19 are manufactured in Vero cells, which are derived from African green monkey kidney tissue. Vero cells are used in production of vaccines for diseases like influenza, rabies, and rotavirus. This is relevant because people sometimes conflate the manufacturing platforms of different vaccines. If you hear that “monkey cells are used to make vaccines,” that statement is true for certain other vaccines but does not apply to the mRNA COVID-19 vaccines from Pfizer and Moderna, which use an entirely cell-free enzymatic process to produce the mRNA, or to the J&J vaccine, which uses a human cell line.

The AstraZeneca vaccine’s use of a chimpanzee adenovirus shell comes closest to involving primate biology, but even there the manufacturing cell line (HEK 293 or derivatives, depending on the production site) is human. The chimpanzee adenovirus Y25 was isolated, sequenced, engineered to be replication-deficient, and then produced in human cells. No monkey cells are part of the COVID-19 vaccine supply chain for any of the vaccines that were widely distributed in the United States or Europe.

How Regulatory Limits Were Set

The 10-nanogram, 200-base-pair standard for residual DNA was established well before COVID-19. It grew out of theoretical risk assessments about what amount of foreign DNA could plausibly cause harm. The concern was twofold: that certain DNA sequences from host cells might carry oncogenes capable of promoting tumor growth, and that DNA from cell lines harboring latent viruses could theoretically be infectious.⁸ The size limit of 200 base pairs was set because very short DNA fragments are considered too small to encode a functional gene or to integrate efficiently into chromosomes.³

These limits were designed for products made in continuous mammalian cell lines and have been applied to biologics like monoclonal antibodies and recombinant proteins for years. Applying the same limits to mRNA vaccines, which are a fundamentally different product category, has raised questions about whether the existing framework is perfectly suited. The DNA in an mRNA vaccine vial is encapsulated within lipid nanoparticles alongside the mRNA, which could affect how it interacts with cells compared to free DNA in a traditional biologic. Regulators are aware of this distinction, and the scientific community is actively working on updated analytical standards for this product class. But none of this suggests that monkey DNA is part of the picture.